Smith & Nephew $240m acquisition looks risky amid Covid-19 pandemic, but analysts say it’s likely to pay dividends
Smith & Nephew sees the acquisition of Integra LifeSciences orthopaedic business as an entry into the shoulder replacement and foot and ankle segments (Credit: Integra LifeSciences)